{"id":"W2483010876","doi":"10.1200/jco.2012.30.15_suppl.3504","title":"Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, <i>K-RAS </i>wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Notre-Dame; Hôtel-Dieu de Québec; Ottawa Hospital; Princess Margaret Cancer Centre; Dr. H. Bliss Murphy Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Chemotherapy; Placebo; Gastroenterology; Refractory (planetary science); Phases of clinical research; Progression-free survival; Surgery; Chemotherapy regimen; Urology; Oncology; Randomized controlled trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003981151,0.002133375,0.00244356,0.0004163351,0.0004589783,0.001420161,0.001344569,0.002021742,0.01033039],"category_scores_gemma":[0.002854798,0.000811366,0.002086305,0.0004372984,0.001109034,0.001013431,0.0005251249,0.003317331,0.001814869],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001215518,"about_ca_system_score_gemma":0.001828785,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001963852,"about_ca_topic_score_gemma":0.004894961,"domain_scores_codex":[0.9989417,0.0007023553,0.00003825295,0.0001191495,0.00005438023,0.0001441197],"domain_scores_gemma":[0.9984502,0.0003795496,0.0002715363,0.0001226536,0.0001353366,0.0006407817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9827999,0.002686514,0.0004586782,0.000328205,0.0008409607,0.00005156005,0.00004601561,0.0005772375,0.002061314,0.0001474236,0.003395537,0.00660663],"study_design_scores_gemma":[0.9758555,0.02116408,0.001044829,0.00002012131,0.0004006768,0.00002296968,0.0000117068,0.0002873137,0.0001829324,0.0001320118,0.0008684538,0.000009362856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9410704,0.007488773,0.00256496,0.004118546,0.001400192,0.01957768,0.01265488,0.0004596935,0.01066488],"genre_scores_gemma":[0.9539305,0.002640182,0.004199326,0.003345221,0.000578639,0.01308976,0.01090765,0.0001040072,0.01120465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01033039,"threshold_uncertainty_score":0.03455865,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1747166709566492,"score_gpt":0.4922278301571239,"score_spread":0.3175111592004747,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}